Epilepsy is a serious condition where abnormal brain activity causes recurring seizures. Current treatments help many patients but have significant challenges: existing medications can be slow-acting, difficult to administer during emergencies, or cause serious side effects. Traditional uses of lidocaine (a common anesthetic) for epilepsy required complicated methods like intravenous drips, and often led to problems like heart issues, stomach problems, and toxic reactions due to high doses.
This invention introduces a much better solution: a special intranasal (nose-administered) formula of lidocaine hydrochloride that can quickly and safely control epileptic seizures. Instead of injections or large doses, patients can receive tiny, carefully measured amounts via simple nasal drops or small inhalers. This method takes advantage of the nose’s direct connection to the brain, enabling rapid delivery, lower doses, and fewer side effects.
The key innovation is the creation of a stable, highly concentrated, and fast-absorbing lidocaine formula. By using smart combinations of solubilizers, absorption enhancers, and viscosity controls, the drug stays effective, safe, and easy to absorb through the nose, ensuring it reaches the brain efficiently without causing harm.
Benefits include
- Immediate action during seizures without the need for hospital intervention.
- Lower risk of toxicity due to precise, small dosages.
- Easier self-administration, even by non-medical personnel.
- Higher patient comfort compared to invasive treatments.
Broader impact
This invention could transform epilepsy treatment, particularly for emergencies, and offers a life-saving alternative where quick action is critical. It could also inspire wider use of intranasal therapies for brain-related conditions, making advanced care more accessible, affordable, and less invasive for millions worldwide.